A place for peculiar ideas.

Research article / 5 minute read

Thymus Degeneration and Regeneration (2021): A Review of What Has Reached Clinical Trials and What Remains in Mice

Most of this dossier consists of patent abstracts that claim to restore the thymus by herbs, light, vibration or extracts, usually judged by organ weight in rodents. A useful counterweight is a 2021 review in Frontiers in Immunology by Maxwell Duah, Lingling Li, Jingyi Shen, Qiu Lan, Bin Pan and Kailin Xu. It surveys why the Thymus Gland degenerates and which regeneration strategies have been tested, and it names the clinical trials behind the few approaches that have reached people. That makes it a practical baseline: it shows what mainstream thymus-regeneration research looks like and how thin the human evidence still is.

Why the thymus needs regenerating at all

The review describes the thymus as the organ where T cells mature. Two kinds of epithelial cell do most of the work. Cortical cells (cTECs) start precursors down the T-cell path and select useful ones. Medullary cells (mTECs) display the body's own proteins so that self-reactive cells can be removed. A transcription factor called FOXN1 is presented as the master regulator of these epithelial cells.

The authors sort damage into two kinds. Acute insults include stress hormones, infections, chemotherapy, radiation, and the graft-versus-host disease (GVHD) that can follow allogeneic stem-cell transplantation. These mostly kill developing thymocytes, and the organ can partly recover. Chronic damage, chiefly age-related Thymic Involution, is described differently: the epithelial compartment itself is lost, FOXN1-positive cells decline, and fat cells and fibroblasts take their place. The review cites one clinical observation to show recovery after acute damage. After chemotherapy, blood markers of new thymic output (CD31+ recent thymic emigrants and sjTREC levels) fell to their lowest point at the end of treatment and recovered within a year.

The paper also discusses COVID-19. It cites work by Cuvelier et al. suggesting that an enlarging thymus, partly driven by IL-7, helps patients cope with virus-induced lymphopenia, and that older patients lose this response. The review presents this as a proposed contributor to higher mortality in the elderly. It does not establish cause and effect.

The menu of strategies

The review's summary table lists ten approaches: sex steroid inhibition, lab-made precursor T cells, thymus transplantation, keratinocyte growth factor (KGF), interleukin-22, growth hormone, RANKL, epidermal growth factor, BMP4 and IL-7. Each is paired with a proposed signalling mechanism, often a named pathway such as PI3K-Akt or JAK/STAT. The authors are frank about the balance. They write that "few clinically proven therapies have been reported to restore the thymus function", while preclinical work suggests other options.

What has reached human trials

The review points to a short list of human studies:

  • Interleukin-7. The review cites trials NCT00684008, NCT00477321, NCT01190111 and NCT01241643, in which glycosylated recombinant human IL-7 was reported to speed T-cell recovery in HIV or transplant patients. The phase I/IIa study NCT00477321 in HIV-1-infected patients is described as safe and well tolerated, with a transient expansion of naive and memory CD4+ and CD8+ T cells. A further study, NCT00839436, in idiopathic CD4+ lymphopenia reported more circulating CD4+ and CD8+ T cells. These are blood counts of T cells. The review does not report imaging of the thymus itself in these trials.
  • Growth hormone. Trial NCT00071240 gave recombinant growth hormone (somatropin) to HIV-infected patients. The review reports increased thymic cellularity and more naive CD4+ and CD8+ T cells. It also cites the TRIIM trial, describing it as 10 healthy men aged 51 to 65 given growth hormone, DHEA and metformin, and mentions the TRIIM-X follow-up in men and women aged 40 to 80 (NCT04375657) as in progress. The dossier's own account, The TRIIM Trial (2019): Growth Hormone, DHEA and Metformin, MRI Evidence of Thymic Regeneration in Nine Men, explains that ten men were enrolled but results come from nine, with no control group.
  • Sex steroid ablation. The review cites clinical work in prostate cancer patients in which hormone ablation was associated with more naive T cells, NK cells and TRECs. A pilot study with the LHRH agonist goserelin after transplantation is reported to have helped T-cell recovery without worsening GVHD. The authors caution that this approach still has to avoid causing hormone-deficiency disorders.

KGF, by contrast, is described in the review only through animal and preclinical findings: protection of thymic tissue and better T-cell production in transplanted mice. No KGF trial identifier is given.

What remains preclinical

For most of the remaining strategies, including IL-22, RANKL, EGF, BMP4, recombinant FOXN1 protein and bioengineered thymus tissue, the review describes mouse or cell-culture work. The most striking results are of this kind. Old mice reportedly showed rejuvenated thymic function after receiving fibroblasts reprogrammed with Foxn1. Lab-made T-cell precursors reportedly settled in the thymus of recipient mice. The review notes that expanded T cells "have not yet proven to be therapeutically effective in clinical settings."

Several of the IL-22 findings come from the authors' own laboratory, including a human transplant study in which plasma IL-22 levels tracked recovery of thymic output. That is a correlation, not a test of IL-22 as a treatment.

What the review does and does not establish

This is a narrative review, not a systematic one. It summarises studies without pooling their data, grading their quality or reporting effect sizes. Its trial evidence measures mostly blood T-cell counts in sick populations (HIV, transplant, lymphopenia, prostate cancer), not reversal of age-related involution in healthy people. Its concluding section acknowledges that key mechanisms remain unclear. It also argues that a regenerative approach favouring only positive or only negative selection could unbalance thymic function. The authors declare no commercial conflicts, and the work was funded by Chinese national and provincial science foundations.

How it fits the dossier

Set beside Thymus Therapy Claims vs. Evidence: The Patent-Abstract Dossier Without Clinical Data and the abstracts in Thymus Therapies: The source archive Patent-Abstract Dossier, the review clarifies the gap. Thymus regeneration is an active research field. Where human evidence exists, it comes from registered trials of specific recombinant proteins or hormone manipulation, mostly in patients with damaged immune systems, and the IL-7 effect on T-cell counts in one HIV trial is described as transient. None of the botanical, device or cosmetic mechanisms in the patent dossier appears among the strategies the review considers. As Patent as Evidence explains, a patent claim does not borrow credibility from a field merely because the field is real.

Reference

  • Duah M, Li L, Shen J, Lan Q, Pan B, Xu K. "Thymus Degeneration and Regeneration." Frontiers in Immunology, 2021 (received 7 May 2021, accepted 16 August 2021). https://pmc.ncbi.nlm.nih.gov/articles/PMC8442952/
Source notes & attribution
  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC8442952/